ArticleOncology research2026
An
Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Photodynamic therapy (PDT) may eradicate residual malignant cells following sarcoma resection, through reactive oxygen species (ROS) mediated cytotoxicity, thus improve clinical outcomes. This study aims to assess the efficacy of 5-aminolevulinic acid (5-ALA) as a photosensitizer in combination with red light (RL) for PDT of bone sarcoma cells Methods: Three bone sarcoma cell lines underwent treatment with 5-ALA and RL or sham-RL (SL). 5-ALA uptake was assessed using flow cytometry. Production of ROS was measured using CellROX Green staining and fluorescence microscopy. Cell viability was assessed using Cell Counting Kit-8 assays. Results: All cell lines showed significant 5-ALA uptake in comparison to the 0 mM control ( Conclusion: 5-ALA-based PDT led to the desired increased production of ROS and reduction in cell viability in all cell lines. These preliminary
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.